Hemostemix Inc · TSXV:HEM

Hemostemix — Investor Presentation (January 2021)

22 slides from Hemostemix's investor presentation, Jan 25, 2021

  1. Slide 1: Tech Pioneer: Safe Efficacious Autologous Treatment of CLI, PAD, Angina

    Slide 1: Tech Pioneer: Safe Efficacious Autologous Treatment of CLI, PAD, Angina

    Tech Pi oneer SAFE EFFICACIOUS AUTOLOGOUS TREATMENT OF CLI, PAD, ANGINA, ISCHEMIC & DILATED CARDIOMYOPATHY JAN 2021 © HEMOSTEMIX INC. ALL RIGHTS RESERVED. TSXV:HEM OTC:HMTXF

  2. Slide 2: Forward-Looking Information

    Slide 2: Forward-Looking Information

    F O RWA R D -L O O K IN G IN F O R M AT IO N This presentation contains forward looking statements that reflect management’s expectations regarding the future growth and results of operational performance including but not limited to the scientific, financial, competitive and business prospects of H

  3. Slide 3: Patented Autologous Stem Cell Therapy Platform

    Slide 3: Patented Autologous Stem Cell Therapy Platform

    PAT E N T E D A U T O L O G O U S S T E M C E L L T H E R A P Y P L AT F O R M Hemostemix Inc. (TSXV:HEM OTC:HMTXF) >300 Patients treated. 91 patents cover five patent families Ongoing 17 Centre International Phase Abstract results show improvement in including automated production of II Clinical Tr

  4. Slide 4: Hemostemix at a Glance

    Slide 4: Hemostemix at a Glance

    H O W S C AL A B L E I S O U R P L AT F O R M ? H E M O S T E M I X – AT A G L AN C E Patented Key Partnerships • 91 Patents issued worldwide • 5 patent families including automation of • License Negotiations Started production patent • By Indication by Country Expandable Platform Data Driven • ACP-

  5. Slide 5: The Importance of Cell Therapy

    Slide 5: The Importance of Cell Therapy

    T H E IM P O R TA N C E O F C E L L T H E R A P Y Disease Trends support need for Strong Government Population and new therapies and Public support Lifestyle Factors • CLI is a major global health • Regenerative medicine is the leading • Aging populations worldwide problem - incidence growing with e

  6. Slide 6: ACP-01 Differentiators

    Slide 6: ACP-01 Differentiators

    A C P -0 1 D IF F E R E N T IATO R S Autologous. Proven safety and Blood draw: safer, less invasive Global portfolio of 91 patents efficacy than fat or bone marrow Including automated production Non-surgical, enhanced cell therapy treatment for restoring circulation to blood starved tissues and orga

  7. Slide 7: ACP-01 Potential Markets

    Slide 7: ACP-01 Potential Markets

    A C P -0 1 P O T E N T IA L M A R K E T S M U L T I P L E C U R R E N T A N D F U T U R E I N D I C AT I O N S P O T E N T I AL Critical Limb Ischemia CLI - Tip of the Iceberg Peripheral Arterial Disease CLI - Estimated total costs up to $248B¹ in US. Angina and CVD Cardiovascular Disease Ischemic R

  8. Slide 8: Why ACP-01 for CLI? It Saves Limbs

    Slide 8: Why ACP-01 for CLI? It Saves Limbs

    W H Y A C P -0 1 F O R C L I? IT S AV E S L IM B S Hope for CLI Patients Facing Amputation 01 02 Extract and enrich patient’s Inject patient’s cell population own cell population from to form new blood vessels, peripheral blood saving limb Self-Donor Simple Quick Uses patient’s own cells, Cell harve

  9. Slide 9: CLI with ACP-01 Improvements Visualized

    Slide 9: CLI with ACP-01 Improvements Visualized

    C L I W IT H A C P- 0 1 IM PROV E M E NT S V IS UA L IZ E D 47 Days post ACP-01 Treatment Before After

  10. Slide 10: Phase II Trial for CLI Update

    Slide 10: Phase II Trial for CLI Update

    P H A S E II T R IA L F O R C L I U P D AT E Randomized, placebo-controlled double blind Phase II clinical trial to confirm the safety and efficacy of ACP-01 US FDA and Health Canada approved trial protocol Phase II Trial CRO All follow-ups completed by Mar FDA and Health Canada 17 sites on-boarded

  11. Slide 11: Phase II CLI Trial Milestones

    Slide 11: Phase II CLI Trial Milestones

    P H A S E II C L I T R IA L M IL E S TO N E S H2 2017 H1 2018 H2 2018 H1 2019 H2 2019 H1 2020 H2 2020 Phase II CLI Trial CRO engaged Health Canada Approval¹ US FDA Approval² Site & Patient Recruiting⁴ First Patient Treatment³ Patient Monitoring⁴ Interim Data⁴ Study Completion⁴ A catalyst for future

  12. Slide 12: ACP-01 Study and Trial History

    Slide 12: ACP-01 Study and Trial History

    A C P -0 1 S T U D Y A N D T R IA L H IS TO RY Study Number of Type of Study Study Location Objective of Study Patients Study Status Design Subjects Pilot Safety/ To assess the feasibility and safety Thailand Open label 6 Diagnosed CLI Completed Feasibility of the implantation To assess safety or ex

  13. Slide 13: ACP-01 Study and Abstract Results

    Slide 13: ACP-01 Study and Abstract Results

    A C P -0 1 S T U D Y A N D A B S T R A C T R E S U LT S ABSTRACT TTLE: AUTOLOGOUS STEM CELL TREATMENT FOR CLI PATIENTS WITH NO REVASCULARIZATION OPTIONS: AN UPDATE OF THE HEMOSTEMIX ACP-01 TRIAL WITH 4.5 YEAR FOLLOW UP Jonathan Misskey MD MHPE¹, Lynn Cunada, RN², Kyle Makofka³, Alan Jacobs MSEE. MD

  14. Slide 14: ACP-01 Study and Abstract Results: Thailand

    Slide 14: ACP-01 Study and Abstract Results: Thailand

    A C P -0 1 S T U D Y A N D A B S T R A C T R E S U LT S SAFETY AND EFFICACY STUDY - Thailand: Purpose: To assess the safety and efficacy of transcoronary injection of angiogenic cells precursors (ACPs) in patients with ischemic cardiomyopathy. Methods: Between 2005 and 2008, 106 ischemic heart disea

  15. Slide 15: Diagnosed Angina Clinical Trial

    Slide 15: Diagnosed Angina Clinical Trial

    A C P -0 1 S T U D Y A N D A B S T R A C T R E S U LT S D IAGNOS E D ANGINA C L INIC AL T RIAL Purpose: To assess the safety and efficacy of intracoronary injection Angiogenic Cell Precursors (“ACP”s) based product for the treatment of patients with chronic stable angina pectoris who were on maximal

  16. Slide 16: Indication Pipeline

    Slide 16: Indication Pipeline

    IN D IC AT IO N P IP E L IN E Development Phase Candidate Indication Status Preclinical Clinical • Currently 17 sites and 65 ACP-01 • Critical limb ischemia • Phase II clinical trial patients enrolled. • Trial ongoing • PAD • Angina Pectoris • Ischemic & dilated • Preparing for Phase II Angina Cardi

  17. Slide 17: Management and Directors

    Slide 17: Management and Directors

    MA NA GE ME NT A ND DIRECT ORS Peter Lacey, ICD.D, Chairman of the Board • Chairman of Cervus Equipment Corporation (CERV.TO), from inception to date. • President and Chief Executive Officer of Cervus Equipment Corporation and its predecessor entities from 1982 to April 2012. • Cervus is a company h

  18. Slide 18: Advisory Board

    Slide 18: Advisory Board

    A D VIS ORY B OA R D Timothy Chang, BA • Currently a Private Investor and an investment committee member of an Asian-based hedge fund with average total AUM of approximately US$1 billion. He has also been a consultant to Newport Healthcare Advisors and to SSG Capital Management. Mr. Chang is a renow

  19. Slide 19: Scientific Advisory Board

    Slide 19: Scientific Advisory Board

    S C IE NT IF IC A D VIS ORY B OA R D Dr. York Hsiang, MB, ChB, MHSc, FRCSC • Professor of Vascular Surgery at University of British Columbia, and Consultant Surgeon at the Vancouver General Hospital • Dr. Hsiang has diverse interests in vascular biology, vascular engineering and clinical epidemiolog

  20. Slide 20: Share Capital Overview

    Slide 20: Share Capital Overview

    S H A R E C A P ITA L O V E RV IE W Share capital structure as of December 31, 2020 ($CAD) Number Ex. Price Expiry or Closing Common Shares Issued and Outstanding 55,535,638 Stock Options 5,342,000 $0.70-$2.00 Apr 2023-Dec 2025 Share Purchase Warrants² 39,241,348 $1.00 Mar 2021-Dec 2021 Finder Warra

  21. Slide 21: Shaping The Future of Medicine

    Slide 21: Shaping The Future of Medicine

    P E R S O N AL I Z E D S T E M C E L L T H E R AP Y T O D AY WO R L D E C O N O M I C F O R U M T E C H N O L OG Y P I O N E E R , 2006 Shaping The Future of Medicine For more Information please contact: Thomas A. Smeenk www.hemostemix.com President and CEO Suite 1150, 707-7th Avenue SW 905-580-4170

  22. Slide 22: Rights of Action for Damages or Rescission

    Slide 22: Rights of Action for Damages or Rescission

    RIGHTS OF ACTION FOR DAMAGES OR RESCISSION The following statutory rights of action for damages or rescission will only apply to a purchaser of securities of the Company in the event that this presentation is deemed to be an offering memorandum pursuant to applicable securities legislation in certai

Source: Internet Archive copy of hemostemix.com

More decks from Hemostemix Inc

All 14 Hemostemix decks